Who
Nathan J. Dowden
President & COO
Company insider
Files Form 4 as: President & COO, Entrada Therapeutics.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 25
- Bought
- $0
- Sold
- $2.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Oct 2021
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $18K2,528 at $7.14 | filing |
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $18K2,528 at $7.14 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code M | $26K15,000 at $1.74 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $230K15,000 at $15.33 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code M | $26K15,000 at $1.74 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $230K15,000 at $15.33 | filing |
| 10 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $155K11,894 at $13.05 | filing |
| 10 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $155K11,894 at $13.05 | filing |
| 9 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K3,116 at $13.02 | filing |
| 9 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K3,116 at $13.02 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $165K14,038 at $11.76 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $165K14,038 at $11.76 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $84K7,223 at $11.66 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $84K7,223 at $11.66 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —55,800 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,200 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,200 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —55,800 at $0.00 | filing |
News
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Nathan J. Dowden; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.